- Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK
- Highlighting biomarker-based diagnostic innovations for RA and axSpA
Vancouver, Canada – April 25, 2025 – Augurex Life Sciences Corp., a leader in biomarker-based diagnostics for autoimmune diseases, today announced its attendance at the British Society for Rheumatology (BSR) 2025 Annual Meeting, taking place April 28–30 in Manchester, UK.
The BSR Annual Meeting is the UK’s largest rheumatology-focused event, bringing together clinicians, researchers, and industry experts to explore the latest advances in the diagnosis, treatment, and management of rheumatic diseases.
At this year’s meeting, Augurex will highlight its diagnostic innovations that support earlier and more accurate identification of rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA)—two chronic conditions where delayed diagnosis remains a significant clinical barrier.
Augurex’s solutions include:
– 14-3-3eta, a well-established biomarker aiding in the diagnosis and management of RA
– Anti-14-3-3eta Multiplex, an emerging tool with potential to advance early detection of axSpA
We look forward to connecting with you at BSR 2025! To learn more, visit:
British Society for Rheumatology (BSR) 2025 Annual Meeting
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, available as JOINTstat® in Canada and Great Britain, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
[email protected]